drugset / Trial / NCT05041426
Letermovir for CMV Prevention After Lung Transplantation
Non-randomizedParallel-groupOpen-labelPrevention
Summary
This is an interventional, open-label, single center, pilot study with historical controls to test the efficacy of letermovir (LET) for the prevention of CMV infection and disease in adult lung transplant recipients (LTRs) with idiopathic pulmonary fibrosis (IPF).
Timeline
- Start
- 2021-12-06
- Primary completion
- 2025-03-03
- Completion
- 2025-03-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Letermovir | Small molecule | 240 mg | Intravenous |
| Subject | Letermovir | Small molecule | 480 mg | Intravenous |
| Comparator | Valganciclovir | Small molecule | — | — |